CDMO Avid Bioservices Inc

Price (delayed)

$15.61

Market cap

$963.83M

P/E Ratio

97.56

Dividend/share

N/A

EPS

$0.16

Enterprise value

$996.36M

Avid Bioservices is a dedicated contract development and manufacturing organization (CDMO) focused on development and CGMP manufacturing of biopharmaceutical drug substances derived from mammalian cell culture. The company provides a ...

Highlights
CDMO's gross profit has surged by 90% year-on-year and by 8% since the previous quarter
CDMO's price to earnings (P/E) is 62% lower than its last 4 quarters average of 257.8
Avid Bioservices's quick ratio has increased by 47% YoY but it has decreased by 12% from the previous quarter
Avid Bioservices's equity has decreased by 34% YoY but it has increased by 11% QoQ

Key stats

What are the main financial stats of CDMO
Market
Shares outstanding
61.74M
Market cap
$963.83M
Enterprise value
$996.36M
Valuations
Price to earnings (P/E)
97.56
Price to book (P/B)
16.99
Price to sales (P/S)
8.3
EV/EBIT
57.41
EV/EBITDA
46.72
EV/Sales
8.59
Earnings
Revenue
$115.98M
EBIT
$17.35M
EBITDA
$21.33M
Free cash flow
-$9.28M
Per share
EPS
$0.16
Free cash flow per share
-$0.15
Book value per share
$0.92
Revenue per share
$1.88
TBVPS
$5.1
Balance sheet
Total assets
$314.1M
Total liabilities
$257.52M
Debt
$182.84M
Equity
$56.58M
Working capital
$126.19M
Liquidity
Debt to equity
3.23
Current ratio
2.63
Quick ratio
2.31
Net debt/EBITDA
1.53
Margins
EBITDA margin
18.4%
Gross margin
32.6%
Net margin
12.1%
Operating margin
15%
Efficiency
Return on assets
3.4%
Return on equity
17%
Return on invested capital
7.9%
Return on capital employed
7.3%
Return on sales
15%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

CDMO stock price

How has the Avid Bioservices stock price performed over time
Intraday
-0.76%
1 week
17.02%
1 month
26.09%
1 year
-37.28%
YTD
-46.5%
QTD
-23.37%

Financial performance

How have Avid Bioservices's revenue and profit performed over time
Revenue
$115.98M
Gross profit
$37.81M
Operating income
$17.44M
Net income
$14.07M
Gross margin
32.6%
Net margin
12.1%
The operating margin has surged by 178% year-on-year but it has declined by 2.6% since the previous quarter
The company's net margin has surged by 120% YoY but it fell by 8% QoQ
CDMO's gross profit has surged by 90% year-on-year and by 8% since the previous quarter
CDMO's revenue is up by 44% year-on-year and by 9% since the previous quarter

Growth

What is Avid Bioservices's growth rate over time

Valuation

What is Avid Bioservices stock price valuation
P/E
97.56
P/B
16.99
P/S
8.3
EV/EBIT
57.41
EV/EBITDA
46.72
EV/Sales
8.59
CDMO's price to earnings (P/E) is 62% lower than its last 4 quarters average of 257.8
The company's EPS rose by 23% QoQ
CDMO's price to book (P/B) is 59% more than its 5-year quarterly average of 10.7 but 38% less than its last 4 quarters average of 27.3
Avid Bioservices's equity has decreased by 34% YoY but it has increased by 11% QoQ
CDMO's revenue is up by 44% year-on-year and by 9% since the previous quarter
CDMO's P/S is 41% below its last 4 quarters average of 14.1 but 14% above its 5-year quarterly average of 7.3

Efficiency

How efficient is Avid Bioservices business performance
The company's return on sales has surged by 173% YoY but it fell by 3.8% QoQ
CDMO's return on equity is up by 33% since the previous quarter
Avid Bioservices's return on invested capital has decreased by 22% QoQ
The return on assets has grown by 3% since the previous quarter

Dividends

What is CDMO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CDMO.

Financial health

How did Avid Bioservices financials performed over time
The total assets is 22% greater than the total liabilities
The total assets has surged by 87% year-on-year and by 4.1% since the previous quarter
Avid Bioservices's quick ratio has increased by 47% YoY but it has decreased by 12% from the previous quarter
Avid Bioservices's equity has decreased by 34% YoY but it has increased by 11% QoQ
The debt to equity is down by 10% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.